Biomerica Inc (Biomerica) develops, manufactures, and markets medical diagnostic products used for the early detection and monitoring of chronic diseases and medical conditions. The company’s diagnostic test kits are used to analyze blood, urine and fecal specimens of the patient to diagnose various diseases and medical complications. It focuses on the development of products for diabetes, gastrointestinal, food intolerances and esoteric tests by utilizing enzyme immunoassay technology. Biomerica’s diagnostic tests are used by hospitals, clinical laboratories, physician’s offices and consumers around the world. The company distributes products in Americas, Europe, Asia, and the Middle East. Biomerica is headquartered in Irvin, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Biomerica Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Biomerica Inc Company Overview
Biomerica Inc Company Snapshot
Biomerica Inc Pipeline Products and Ongoing Clinical Trials Overview
Biomerica Inc – Pipeline Analysis Overview
Business Description
Biomerica Inc - Key Facts
Biomerica Inc - Major Products and Services
Biomerica Inc Pipeline Products by Development Stage
Serological ELISA Test - COVID-19 Product Overview
Biomerica Inc - Key Competitors
Biomerica Inc - Key Employees
Biomerica Inc - Key Employee Biographies
Biomerica Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Biomerica Inc, Recent Developments
Jun 21, 2023: Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
Oct 13, 2022: Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
Aug 30, 2022: Biomerica Plans Launch of InFoods IBS Test; Names Robert Carlson as Chief Commercial Officer
Apr 14, 2022: Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
Jan 13, 2022: Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
Dec 16, 2021: Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
Oct 15, 2021: Biomerica Reports Results for Fiscal First Quarter ended August 31, 2021
Jan 07, 2020: Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods irritable bowel syndrome (IBS) diagnostic guided therapy clinical trial
Oct 16, 2019: Biomerica reports 1st quarter fiscal 2020 financials
Aug 30, 2019: Biomerica announces fiscal year end 2019 financial results